Have a feature idea you'd love to see implemented?
Let us know!
NVNO enVVeno Medical Corp
Price (delayed)
$3.3
Market cap
$57.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.29
Enterprise value
$41.1M
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product
Highlights
The equity has surged by 90% year-on-year and by 23% since the previous quarter
The EPS has grown by 40% year-on-year and by 7% since the previous quarter
NVNO's quick ratio has soared by 72% YoY but it is down by 6% QoQ
enVVeno Medical's net income has increased by 12% YoY but it has decreased by 3.1% from the previous quarter
Key stats
What are the main financial stats of NVNO
Market
Valuations
Earnings
Shares outstanding
17.54M
Market cap
$57.87M
Enterprise value
$41.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.93
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$21.24M
EBITDA
-$20.7M
Free cash flow
-$16.74M
Per share
Balance sheet
Liquidity
EPS
-$1.29
Free cash flow per share
-$1.04
Book value per share
$3.55
Revenue per share
$0
TBVPS
$3.14
Total assets
$50.39M
Total liabilities
$3.02M
Debt
$1.15M
Equity
$47.37M
Working capital
$46.82M
Debt to equity
0.02
Current ratio
22.01
Quick ratio
21.7
Net debt/EBITDA
0.81
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-46%
Return on equity
-48.7%
Return on invested capital
-54.1%
Return on capital employed
-44.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVNO stock price
How has the enVVeno Medical stock price performed over time
Intraday
-2.08%
1 week
-3.23%
1 month
-2.08%
1 year
-14.51%
YTD
-35.8%
QTD
-1.79%
Financial performance
How have enVVeno Medical's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.41M
Net income
-$21.24M
Gross margin
N/A
Net margin
N/A
enVVeno Medical's net income has increased by 12% YoY but it has decreased by 3.1% from the previous quarter
enVVeno Medical's operating income has increased by 8% YoY but it has decreased by 3.6% QoQ
Growth
What is enVVeno Medical's growth rate over time
Valuation
What is enVVeno Medical stock price valuation
P/E
N/A
P/B
0.93
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 40% year-on-year and by 7% since the previous quarter
The equity has surged by 90% year-on-year and by 23% since the previous quarter
The price to book (P/B) is 71% lower than the 5-year quarterly average of 3.2 and 38% lower than the last 4 quarters average of 1.5
Efficiency
How efficient is enVVeno Medical business performance
NVNO's ROE is up by 36% year-on-year and by 10% since the previous quarter
The company's return on assets rose by 34% YoY and by 9% QoQ
The ROIC has grown by 32% YoY and by 2.7% from the previous quarter
Dividends
What is NVNO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVNO.
Financial health
How did enVVeno Medical financials performed over time
enVVeno Medical's total assets has soared by 79% YoY and by 23% from the previous quarter
NVNO's quick ratio has soared by 72% YoY but it is down by 6% QoQ
NVNO's debt is 98% less than its equity
The equity has surged by 90% year-on-year and by 23% since the previous quarter
The company's debt to equity has shrunk by 67% YoY and by 33% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.